"We welcome the concept of NICE using a broader definition of value in its assessment of medicines in order to reflect more fully the value they bring to patients and society.
"We need to ensure that the new system encourages and endorses the use of the innovative medicines that patients need. It is too early to understand the impact that the new proposals will have on future access to medicines until they are published and we are looking forward to reviewing the detail of the proposals, as part of the consultation NICE will be conducting, when they become available."
ABPI Press Office
Tel: +44 (0) 20 7747 1441
Mobile: +44 (0) 7850 312064
Notes to editor
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.